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http:WHAT THIS PAPER ADDS
This study addresses the changes in results following repair of ruptured abdominal aortic aneurysms at a single
centre following introduction of the IMPROVE trial protocol. While survival following open surgical repair
remained unchanged, survival following endovascular repair deteriorated signiﬁcantly when compared with
previous results. This suggests that whereas there may be a survival beneﬁt for endovascular repair in selected
patients, this may not be the case in an unselected cohort.Objectives: The ﬁrst large-scale randomised trial (Immediate Management of the Patient with Rupture: Open
Versus Endovascular repair [IMPROVE]) for endovascular repair of ruptured abdominal aortic aneurysm (rEVAR)
has recently ﬁnished recruiting patients. The aim of this study was to examine the impact on survival after rEVAR
when the IMPROVE protocol was initiated in a high volume abdominal aortic aneurysm (AAA) centre previously
performing rEVAR.
Methods: One hundred and sixty-nine patients requiring emergency infrarenal AAA repair from January 2006 to
April 2013 were included. Eighty-four patients were treated before (38 rEVAR, 46 open) and 85 (31 rEVAR, 54
open) were treated during the trial period. A retrospective analysis was performed.
Results: Before the trial, there was a signiﬁcant survival beneﬁt for rEVAR over open repair (90-day mortality 13%
vs. 30%, p ¼ .04, difference remained signiﬁcant up to 2 years postoperatively). This survival beneﬁt was lost
after starting randomisation (90-day mortality 35% vs. 33%, p ¼ .93). There was an increase in overall 30-day
mortality from 15% to 31% (p ¼ .02), while there was no change for open repair (p ¼ .438). There was a
signiﬁcant decrease in general anaesthetic use (p ¼ .002) for patients treated during the trial. Randomised
patients had shorter hospital and intensive treatment unit stays (p ¼ .006 and p ¼ .03 respectively).
Conclusions: The change in survival seen during the IMROVE trial highlights the need for randomised rather than
cohort data to eliminate selection bias. These results from a single centre reinforce those recently reported in
IMPROVE.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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There has been intense debate over the role of randomised
trials for endovascular repair of ruptured abdominal aortic
aneurysms (rAAAs). Since the technique was ﬁrst described
in 1994, initial uptake in specialist centres led to the pub-
lication of combined world data showing favourable early
results.1 However, meta-analysed cohort data from more
comprehensive literature have produced mixed results.2e4
Some enthusiastically found short-term survival beneﬁts
compared with open repair,2 while others were more
pragmatic, citing heavy selection and publication bias inresponding author. G.K. Ambler, Department of Vascular Surgery,
dge University Hospitals NHS Foundation Trust, Hills Road, Cam-
CB2 0QQ, UK.
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//dx.doi.org/10.1016/j.ejvs.2014.01.011meta-analysed studies.3,4 The implication was that true
“gold standard” evidence was needed before deﬁnitive
recommendations on widespread adoption could be made.
The Immediate Management of the Patient with Rupture:
Open Versus Endovascular repair (IMPROVE) randomised
trial is an attempt to provide this evidence, and has recently
completed recruitment in the UK.5,6
While the 30-day results from IMPROVE have been
recently reported,7 outcomes from centres which were
already performing endovascular repair of rAAA (rEVAR)
successfully before switching to randomisation under the
trial protocol are unknown.8 Detractors of randomised
studies for rAAA have suggested that the trial is ethically
questionable, as rEVAR results were likely to stay the same
while patients randomised to open surgical repair (OSR)
would have worse outcomes, resulting in net harm to the
enrolled patient population.9 Proponents suggest that out-
comes are impossible to predict, citing recognised problems
with the current retrospective literature and the fact that
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results.10,11 The aim of this study was therefore to examine
rAAA outcomes in a high volume AAA centre previously
performing rEVAR before and after the implementation of
the IMPROVE trial protocol to assess impact on patient
survival.
METHODS
All patients were treated at Addenbrooke’s Hospital as part
of the local vascular network. The study period included
January 2006 to April 2013, with follow-up until July 2013.
This marks the time period since out of hours EVAR was
available at Addenbrooke’s. Recruitment for IMPROVE
started in September 2009.5,6 All patients were assessed
and treated by specialist vascular surgeons. If EVAR was
performed, specialist interventional radiologists were al-
ways involved. Permissive hypotension at 100 mmHg sys-
tolic pressure was allowed for all patients. A senior
anaesthetist was present for all procedures, including those
under local anaesthetic. EVAR was performed with a C arm
in theatre by a team consisting of at least one consultant
vascular surgeon and one consultant vascular interventional
radiologist. Postoperatively patients went to high de-
pendency or intensive care depending on clinical need.
Initial experiences of rEVAR at Addenbrooke’s, including
results from the early part of the study period, have been
published previously.8,12
A retrospective analysis of a prospectively maintained
database was performed. Since randomising into IMPROVE,
these data have been held by the local trial co-ordinator.
The database was cross-referenced with the electronic
medical record (eMR) browser for error checking and
mortality statistics. eMR is linked to the UK Ofﬁce for Na-
tional Statistics for mortality reporting. Any data not avail-
able on eMR were obtained directly from patient notes. No
patients were lost to follow up.
Analysis was principally performed as treated rather than
on an intention to treat IMPROVE protocol. The ManneFigure 1. Flow chart showing division of patients into groups. Note. rA
aneurysm repair; OSR ¼ open surgical repair.Whitney U test was used to assess differences between
lengths of stay. The Fisher exact test was used to test for
signiﬁcance between individual group characteristics.
KaplaneMeier estimates were used to examine results for 5
years of follow up, but 2-year data are reported due to the
high attrition rate after this time.13 The log rank test was
used to compare survival estimates. Confounder adjust-
ment was performed using Cox proportional hazards
modelling to account for differences in age; gender; history
of diabetes, ischaemic heart disease, or cerebrovascular
disease; and preoperative medications. Data analysis was
carried out with the R statistical package14 version 3.0.1
with the “survival” add-on package15 version 2.37-4 loaded
for survival analysis. The IMPROVE trial is registered as
ISRCTN 48334791, and local ethical approval has been
granted for recruitment within this trial. The present study
was carried out as part of routine local service evaluation
within the trial and so was not deemed to require separate
ethical approval.
RESULTS
One hundred and seventy-nine patients presented with
ruptured AAA from January 2006 to April 2013 (Fig. 1). Basic
demographics for patients treated before and during
IMPROVE are presented in Table 1. Sixty-nine (39%) of
these underwent rEVAR and one hundred (56%) underwent
OSR. Ten patients (6%) were not offered or were refused
treatment and were palliated so were not analysed. Thirty-
seven patients were randomised into the IMPROVE trial, of
which thirty-ﬁve underwent surgery. Fifty patients (28%)
were treated during the IMPROVE time period but were not
randomised. The most common reason for this was that
they had already undergone computed tomography (CT)
scanning and suitability for EVAR was known at the time of
referral. Two (3%) EVAR and four (4%) OSR died in theatre.
One hundred and sixty-nine patients (94% of those pre-
senting with ruptured AAA) were therefore available for
analysis.AA ¼ ruptured abdominal aortic aneurysm; EVAR ¼ endovascular
Table 1. Demographics for patients treated before and during
IMPROVE.
Before
IMPROVE
(n ¼ 84)
During
IMPROVE
(n ¼ 85)
p
Age (median  IQR) 78.4  7.3 75.4  11.6 .06
Gender (M:F) 71:13 72:13 1.0
ITU days
(median  IQR)
3  15 2  5 .08
Total admission days
(median  IQR)
14  23.5 10  17 .04
AUI:bifurcated graft
(EVAR only)
23:15 21:10 .62
General:local
anaesthetic (EVAR
only)
31:7 14:17 .002
Preoperative markers
Lowest systolic BP
(median  IQR)
90  46.5 88  46 .57
Highest heart rate
(median  IQR)
80  35 86  27 .65
Ischaemic heart
disease
42% 40% .88
Cerebrovascular
disease
9% 7% .59
Diabetes 7% 6% .77
Creatinine
(median  IQR)
129  70.2 133  63 .30
Preoperative medication
Antiplatelet/
anticoagulation (%)
57 48 .28
Beta blocker (%) 23 23 1.0
Statin (%) 52 46 .54
Note. IQR ¼ interquartile range; ITU ¼ intensive treatment unit;
AUI ¼ aorto-uni iliac.
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Figure 2. Comparative survival of ruptured abdominal aortic
aneurysm repair before and during the IMPROVE trial. The solid
line shows survival pre-IMPROVE, the dashed line shows survival
during the trial period.
390 G.K. Ambler et al.Eighty-four patients (50%) were treated for rAAA pre-
IMPROVE and 85 (50%) were treated during the trial. A
total of 69 patients underwent rEVAR: 38 (55%) pre-
IMPROVE and 31 (45%) during the trial. A total of 100 pa-
tients underwent OSR: 46 pre-IMPROVE and 54 during the
trial. During the trial, 16 patients were randomised to CT
scan followed by EVAR if appropriate, of whom 10 (63%)
went on to have EVAR and six had OSR. Nineteen patients
were randomised to OSR, of whom 16 (84%) had OSR and
three were treated with EVAR. The difference in crossover
rate was not signiﬁcant (p ¼ .25). Patients who were
randomised within the trial had signiﬁcantly reduced total
admission days (p ¼ .002) and intensive treatment unit
(ITU) stay (p ¼ .01) when compared with patients who were
not randomised.
The delay from presentation to EVAR was a median of 3
hours 31 minutes (interquartile range [IQR] 1 hour 24 mi-
nutes to 7 hours 55 minutes) before IMPROVE, which was
signiﬁcantly longer than for patients undergoing OSR (me-
dian 1 hour 15 minutes, IQR 45 minutes to 2 hours 18
minutes; p < .0001). This improved during the trial, with no
signiﬁcant difference in time to theatre being observed
between groups during the trial period (median 1 hour 1
minute, IQR 43 minutes to 2 hours 26 minutes for EVAR vs.1 hour 13 minutes, IQR 39 minutes to 1 hour 36 minutes for
OSR; p ¼ .87).Survival before and during IMPROVE
Thirty-day mortality for the 84 patients treated pre-
IMPROVE was 15%. Thirty-day mortality for the 85 pa-
tients treated during the trial was 31%. There was a sig-
niﬁcant survival advantage for patients treated pre-
IMPROVE at 30 days (log rank chi square 5.5, p ¼ .019),
but the difference became non-signiﬁcant at later time
points. This survival advantage was present exclusively in
the rEVAR group (log rank chi square 8.4, p ¼ .004), and
persisted in this group beyond 2 years (log rank chi square
4.9, p ¼ .03). This survival advantage persisted throughout
follow-up after confounder adjustment (hazard ratio of
death following OSR over rEVAR 2.8, p ¼ .006). The sur-
vival beneﬁt of the rEVAR group before the trial was also
reﬂected in improved survival comparison with OSR during
this period (log rank chi square 4.2, p ¼ .04 at 2 years).
This beneﬁt of rEVAR over OSR has been lost since the
trial started (log rank chi square 0.1, p ¼ .79) after
adjusting for confounders. The analysis was repeated for
patients randomised within the trial, but no survival dif-
ference between procedures was seen in this subgroup on
an as-treated basis, and there was no survival difference
between patients who were randomised and those who
were not.
If the survival advantage of rEVAR observed during the
pre-IMPROVE period had been maintained during the trial,
the study would have had 98% power to detect a survival
beneﬁt at the 5% level, so the study was adequately
powered.
Fig. 2 shows survival curves pre-IMPROVE; Fig. 3 shows
separate survival curves for the different procedures.
Figure 3. Comparative survival before and during IMPROVE by
procedure. The solid lines show survival prior to commencement
of the IMPROVE trial, the dashed lines show survival during the
trial. Black lines show ruptured EVAR survival, grey lines show
ruptured OSR survival. Note. EVAR ¼ endovascular aneurysm
repair; OSR ¼ open surgical repair.
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Patients treated with EVAR during the IMPROVE trial were
in general younger (median age 74 vs. 79 years, p ¼ .03),
and were more likely to be treated under local anaesthetic
(p ¼ .002). Although there was no signiﬁcant difference in
length of stay before and during the trial, there was a sig-
niﬁcant reduction in ITU stay (p ¼ .03) and total admission
days (p ¼ .006) for the patients treated with rEVAR within
the trial, when compared with those who were not treated
within the trial. There was a trend towards shorter neck
length and increased neck angulation in the group treated
during the IMPROVE trial, though these trends did not
reach signiﬁcance (mean  SD neck length in IMPROVE
group 2.9  1.4 cm vs. 3.6  2.8 cm, p ¼ .20; mean  SD
neck angulation in IMPROVE group 47  22 vs. 40  21,
p ¼ .18).
Overall 30-day mortality for all EVAR patients was 13%.
Three-, 12-, and 24-month survival was 77%, 74%, and 66%
respectively. Before IMPROVE these ﬁgures were 87%, 84%,
and 76%, which fell to 65%, 61%, and 53% respectively
during the trial. Fig. 3 shows comparative survival for pa-
tients undergoing EVAR or OSR before and during
IMPROVE.
Open survival
Overall 30-day mortality in the OSR group was 30%. Three-,
12- and 24-month survival was 68%, 63%, and 58%
respectively. Fig. 3 shows comparative survival for patientsundergoing OSR before and during IMPROVE. There was no
signiﬁcant difference in mortality before IMPROVE
compared with the group treated during the trial (log rank
chi square 0.6, p ¼ .438): pre-IMPROVE cumulative survival
at 3 and 12 months was 70% and 63%, during it was 67%
and 63% respectively.
Patients undergoing OSR within the trial also had a sig-
niﬁcant reduction in ITU stay (p ¼ .047) and a reduction in
total admission days, though this was not signiﬁcant
(p ¼ .055).EVAR follow-up and reintervention
There was no signiﬁcant difference between reinterventions
before and during IMPROVE groups (p ¼ .59). There were
two inpatient reinterventions during the primary admission
in each EVAR group: one type 2 endoleak requiring inter-
vention due to sac expansion in both groups; and one limb
occlusion requiring femoral crossover grafting in both
groups.
There were 11 (29%) long-term reinterventions in the
group pre-IMPROVE: four type 1 endoleaks, two type 2
endoleaks, two limb occlusions requiring crossover grafting,
two limb kinks requiring stenting, and one limb dislocation.
There have been six reinterventions for the IMPROVE group
(19%): two type 1 endoleaks, two infected crossover grafts
requiring removal and axillo-femoral bypass, one occluded
crossover graft requiring thrombectomy, and one limb kink
requiring stenting.
DISCUSSION
The major ﬁnding was that after starting randomisation into
the IMPROVE protocol, the survival beneﬁt for rEVAR over
OSR repair was lost. Survival for rEVAR showed a signiﬁcant
decrease while survival for OSR was unchanged compared
with pre-IMPROVE. There was a signiﬁcant decrease in ITU
stay (p ¼ .01), total admission days (p ¼ .002), and general
anaesthetic use (p ¼ .002) for patients in the IMPROVE trial.
The strengths of these data are that the database was
maintained prospectively from electronic medical records
used to code Hospital Episode Statistics data which appears
to be accurate for rAAA.16 The data since IMPROVE have
been maintained by the trial investigators, again reducing
concern over error in retrospective data. Having said this,
the pre-IMPROVE data were collected retrospectively for
some variables and is therefore subject to the usual
limitations.
Not all patients presenting since 2009 have been rand-
omised, and this may produce bias in the dataset. However,
this was almost entirely due to either individual consultant
selection, with some randomising all patients, or prior
knowledge of suitability for EVAR, making them ineligible,
reducing this concern to some extent.
Therefore, implementing the IMPROVE protocol reduced
survival in rEVAR patients without changing it for patients
undergoing OSR. There was no reason for this found when
patient demographics were compared (Table 1). The most
probable explanation is that this effect was due to bias from
392 G.K. Ambler et al.selecting patients with more suitable anatomy for EVAR
pre-IMPROVE. This may have caused operators to push the
limits of EVAR devices by aggressive utilisation outside the
instructions for use (IFU) during the trial.17,18 This only adds
to arguments for the value of the IMPROVE trial, as previ-
ously published survival results for rEVAR may be better
than true outcomes when patients are unselected.1
The larger worldwide cohort studies for rEVAR show a 30-
day mortality ranging from 21% to 32%.1,2,19 Thirty-day
mortality pre-IMPROVE in this centre was 14%, which has
now increased to 22%. This may mean the higher mortality
centres were already treating more unwell or unstable pa-
tients. Importantly, however, results of all patients pre-
senting here have worsened since randomisation. There is
an argument that this would always be the outcome of a
randomised trial for rAAA, as patients with borderline
suitability for rEVAR are treated in a way in which they were
not before the trial. Pushing the limits of the technology
and the EVAR teams’ knowledge of rEVAR has worsened
EVAR outcomes by selecting patients who will not be
treated in this way in the future, irrespective of the results
of the trial. In addition, it is possible that outcomes for OSR
may have been subtly improved by the inclusion of patients
with anatomy suitable for EVAR, as it has been shown that
these patients also do better when treated with OSR.20
Indeed, both neck length and angulation were more
adverse in the EVAR group treated during the trial, although
these results did not reach signiﬁcance; so it is possible that
anatomic unsuitability has resulted in deteriorating
outcomes.
One possible source of bias is that, while a specialist
vascular surgeon was always involved in both assessment
and treatment of all patients, those patients treated with
rEVAR also beneﬁtted from the involvement of a specialist
interventional radiologist. This may explain better early re-
sults of rEVAR before IMPROVE, although it cannot explain
the subsequent ﬁndings.
A reduction in intensive care stay and hospital stay are
two beneﬁts of rEVAR over open repair. Although not
assessed here, postoperative quality of life for rEVAR pa-
tients may be faster to return to preoperative levels than
for open patients, which is important in a group with such
poor long-term survival.21,22 As a consequence, even if
there is no survival beneﬁt of rEVAR over OSR, quality of life
improvements may make it a superior therapy overall, at
least for a subset of patients.23
The 30-day outcomes from the IMPROVE trial have been
recently reported and have demonstrated no overall dif-
ference in mortality between an endovascular ﬁrst strategy
compared with open repair.7 The reported mortalities in
both groups were very similar to those in our patients after
we started randomisation, despite the majority of our
cohort being treated outside the trial protocol.
The Cambridge Vascular Unit was relatively high on the
learning curve before starting randomisation, illustrated by
the increasing utilisation of local anaesthetic and reducing
time to theatre for those patients treated with rEVAR dur-
ing the trial period, though small delays in getting patientsto theatre have previously been shown not to impact sur-
vival signiﬁcantly.24 The centre also had better survival for
open ruptures than national UK data even before random-
isation, and results may be different in the full trial data-
set.25 Additionally, crossover from EVAR to open after
randomisation was low, which may not be the case
nationwide leading to a poorer open survival in line with
previous cohort data.
In conclusion, the introduction of randomising patients
with rAAA led to a loss in the survival beneﬁt of rEVAR over
OSR. This was explained by a decreased survival in patients
treated by EVAR and unchanged survival in those under-
going OSR. The effect has been to worsen outcomes of
rEVAR away from the results commonly quoted from cohort
data. These ﬁndings reﬂect those recently reported in
IMPROVE, and selection bias may explain the low mortality
rates for rEVAR in the historical cohort.
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